Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sirna Therapeutics

Request full access

Biotech company using RNA interference-based therapies to change how diseases are treated

San Francisco, United StatesFounded 1992Biotech & Life Sciences

About Sirna Therapeutics

Sirna Therapeutics was a biotechnology company that specialized in the research and development of therapies based on RNA interference (RNAi). The company's primary focus was on small interfering RNA (siRNA), which are molecules capable of silencing specific genes associated with diseases. Sirna's business model revolved around leveraging its proprietary RNAi technology to create a pipeline of drug candidates for various human diseases. A notable milestone for the company was initiating the first-ever clinical trial for an siRNA-based drug, which targeted age-related macular degeneration (AMD), a common eye condition.

The company's market was the pharmaceutical and biotechnology industry, with a focus on therapies for genetic and other diseases that could be addressed by gene silencing. Sirna Therapeutics was acquired by Merck & Co. in 2006 for approximately $1.1 billion. This acquisition provided Merck with a significant entry into the RNAi field. However, in 2014, Merck sold Sirna Therapeutics to Alnylam Pharmaceuticals for $175 million. This transaction included Sirna's intellectual property, pre-clinical drug candidates, and other assets related to RNAi technology, which Alnylam, a leader in the RNAi space, integrated into its own development programs.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2006
Outcome tier
Unicorn$1–10B valuation tier

Sirna Therapeutics in the San Francisco ecosystem

Live from Dealroom

The Sirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later6 investors entered at this stage

Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Patents

Estimated portfolio value
$62M

26 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sirna Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.